The Dual Inhibition of Met and EGFR by ME22S, a Novel Met/EGFR Bispecific Monoclonal Antibody, Suppresses the Proliferation and Invasion of Laryngeal Cancer

Annals of Surgical Oncology

Volumn 23, Issue 6, 2016, Pages 2046-2053

  Lee, Bok Soon ^a   Kim, Haeng Jun ^a,b   Hwang, Jae Woong ^c   Cheong, Kwang Ho ^c   Kim, Kyung Ah ^c   Cha, Hyun Young ^a   Lee, Ji Min ^c   Kim, Chul Ho ^a,b  

^a Stem Cell Differentiation Laboratory   (South Korea)

^b Ajou University   (South Korea)

^c Samsung Medical Center   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ME 22S; MONOCLONAL ANTIBODY; PROTEIN KINASE B; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG; BISPECIFIC ANTIBODY; EGFR PROTEIN, HUMAN; MET PROTEIN, HUMAN; TUMOR MARKER;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER INHIBITION; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SCREENING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LARYNX CARCINOMA; TUMOR INVASION; WOUND HEALING; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; CELL MOTION; DRUG EFFECTS; LARYNX TUMOR; MALE; METABOLISM; MOUSE; PATHOLOGY; TUMOR CELL CULTURE;

ANIMALS; ANTIBODIES, BISPECIFIC; BIOMARKERS, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; HUMANS; LARYNGEAL NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; NEOPLASM INVASIVENESS; PROTO-ONCOGENE PROTEINS C-MET; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84955240017     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-015-5084-0     Document Type: Article

References (29)

1. Schultz P. Vocal fold cancer. Eur Ann OtorhinolaryngolHead Neck Dis. 2011;128:301–8.
2. Tomeh C, Holsinger FC. Laryngeal cancer. Curr Opin Otolaryngol Head NeckSurg. 2014;22:147–53.
3. Zarnegar R, Michalopoulos GK. The many faces of hepatocyte growth factor: from hepatopoiesis to hematopoiesis. J Cell Biol. 1995;129:1177–80.
4. Dong G, Chen Z, Li ZY, Yeh NT, Bancroft CC, Van Waes C. Hepatocyte growth factor/scatter factor-induced activation of MEK and PI3 K signal pathways contributes to expression of proangiogenic cytokines interleukin-8 and vascular endothelial growth factor in head and neck squamous cell carcinoma. Cancer Res. 2001;61:5911–8.
5. Stoker M, Gherardi E, Perryman M, Gray J. Scatter factor is a fibroblast-derived modulator of epithelial cell mobility. Nature. 1987;327:239–42.
6. Lau KM, McGlade CJ. Numb is a negative regulator of HGF dependent cell scattering and Rac1 activation. Exp Cell Res. 2011;317:539–51.
7. Okano J, Shiota G, Matsumoto K, et al. Hepatocyte growth factor exerts a proliferative effect on oval cells through the PI3K/AKT signaling pathway. BiochemBiophys Res Commun. 2003;309:298–304.
8. Bussolino F, Di Renzo MF, Ziche M, et al. Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J Cell Biol. 1992;119:629–41.
9. Raymond E, Faivre S, Armand JP. Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy. Drugs. 2000;60 Suppl 1:15–23 (discussion 41–2).
10. Luetteke NC, Qiu TH, Fenton SE, et al. Targeted inactivation of the EGF and amphiregulin genes reveals distinct roles for EGF receptor ligands in mouse mammary gland development. Development. 1999;126:2739–50.
11. Holbro T, Civenni G, Hynes NE. The ErbB receptors and their role in cancer progression. Exp Cell Res. 2003;284:99–110.
12. Cohen RB. Current challenges and clinical investigations of epidermal growth factor receptor (EGFR)- and ErbB family-targeted agents in the treatment of head and neck squamous cell carcinoma (HNSCC). Cancer Treat Rev. 2014;40:567–77.
13. Schmitz S, Ang KK, Vermorken J, et al. Targeted therapies for squamous cell carcinoma of the head and neck: current knowledge and future directions. Cancer Treat Rev. 2014;40:390–404.
14. Kim CH, Lee JS, Kang SO, Bae JH, Hong SP, Kahng H. Serum hepatocyte growth factor as a marker of tumor activity in head and neck squamous cell carcinoma. Oral Oncol. 2007;43:1021–5.
15. Kim CH, Koh YW, Han JH, et al. c-Met expression as an indicator of survival outcome in patients with oral tongue carcinoma. Head Neck. 2010;32:1655–64.
16. Bonine-Summers AR, Aakre ME, Brown KA, et al. Epidermal growth factor receptor plays a significant role in hepatocyte growth factor mediated biological responses in mammary epithelial cells. Cancer Biol Ther. 2007;6:561–70.
17. Xu H, Stabile LP, Gubish CT, Gooding WE, Grandis JR, Siegfried JM. Dual blockade of EGFR and c-Met abrogates redundant signaling and proliferation in head and neck carcinoma cells. Clin Cancer Res. 2011;17:4425–38.
18. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007;316:1039–43.
19. Sawatsubashi M, Sasatomi E, Mizokami H, Tokunaga O, Shin T. Expression of c-Met in laryngeal carcinoma. Virchows Arch. 1998;432:331–5.
20. So WK, Fan Q, Lau MT, Qiu X, Cheng JC, Leung PC. Amphiregulin induces human ovarian cancer cell invasion by down-regulating E-cadherin expression. FEBS Lett. 2014.
21. Kim SY, Chu KC, Lee HR, Lee KS, Carey TE. Establishment and characterization of nine new head and neck cancer cell lines. Acta Otolaryngol. 1997;117:775–84.
22. Lee JM, Kim B, Lee SB, et al. Cbl-independent degradation of Met: ways to avoid agonism of bivalent Met-targeting antibody. Oncogene. 2014;33:34–43.
23. Lee BS, Kang S, Kim KA, et al. Met degradation by SAIT301, a Met monoclonal antibody, reduces the invasion and migration of nasopharyngeal cancer cells via inhibition of EGR-1 expression. CellDeath Dis. 2014;5:e1159.
24. Longati P, Bardelli A, Ponzetto C, Naldini L, Comoglio PM. Tyrosines 1234-1235 are critical for activation of the tyrosine kinase encoded by the MET proto-oncogene (HGF receptor). Oncogene. 1994;9:49–57.
25. Yucel OT, Sungur A, Kaya S. c-met overexpression in supraglottic laryngeal squamous cell carcinoma and its relation to lymph node metastases. OtolaryngolHeadNeck Surg. 2004;130:698–703.
26. Zhu X, Zhang F, Zhang W, He J, Zhao Y, Chen X. Prognostic role of epidermal growth factor receptor in head and neck cancer: a meta-analysis. J Surg Oncol. 2013;108:387–97.
27. De Herdt MJ, Baatenburg de Jong RJ. HGF and c-MET as potential orchestrators of invasive growth in head and neck squamous cell carcinoma. Front Biosci. 2008;13:2516–26.
28. Leroy P, Mostov KE. Slug is required for cell survival during partial epithelial-mesenchymal transition of HGF-induced tubulogenesis. Mol Biol Cell. 2007;18:1943–1952.
29. Prince A, Aguirre-Ghizo J, Genden E, Posner M, Sikora A. Head and neck squamous cell carcinoma: new translational therapies. Mt Sinai J Med. 2010;77:684–99.